Angitia Biopharmaceuticals, a Woodland Hills, CA-based biotech targeted on critical musculoskeletal illnesses, raised $120M in Sequence C funding.
The spherical was led by Bain Capital Life Sciences with participation from Janus Henderson and OrbiMed, 3H Well being Funding, Yonghua Capital, Legend Capital, and Elikon Enterprise.
Along with the financing, Dr. Norbert Riedel, Ph.D., will be a part of the Firm’s Board of Administrators.
The corporate intends to make use of the funds to help improvement of its pipeline of novel, differentiated remedies, together with AGA2118, AGA2115, AGA111 and different pipeline belongings for the therapy of significant musculoskeletal illnesses.
Led by CEO Dr. David Ke, Angitia Biopharmaceuticals is a clinical-stage biotechnology firm targeted on the invention and improvement of revolutionary therapeutics for critical musculoskeletal illnesses. It’s at the moment learning 3 biologic product candidates within the clinic for the therapy of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion.
Angitia is advancing AGA2118 and AGA2115, bispecific antibodies focusing on sclerostin and DKK1, by way of scientific improvement for osteoporosis and osteogenesis imperfecta (OI), respectively. The 2 molecules signify the following technology of dual-acting remedies for skeletal illness, growing bone formation and lowering bone resorption. With these two bispecifics, Angitia seeks to advertise stronger, extra organized skeletal improvement in sufferers. The corporate can be growing AGA111, a biologic to advertise spinal fusion in sufferers with degenerative disc illness.
FinSMEs
11/12/2024
